Title : Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.

Pub. Date : 2021 Nov

PMID : 34309133






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Rapid progression of metastatic pancreatic adenocarcinoma during platinum-based therapy in a patient harboring a pathogenic BRCA2 germline variant. Platinum BRCA2 DNA repair associated Homo sapiens
2 (3, 4) In contrast, platinum-based therapies would be predicted to be significantly less effective for PDACs in patients with pathogenic BRCA germline variants who have cancers which lack BRCA LOH. Platinum BRCA2 DNA repair associated Homo sapiens
3 (3, 4) In contrast, platinum-based therapies would be predicted to be significantly less effective for PDACs in patients with pathogenic BRCA germline variants who have cancers which lack BRCA LOH. Platinum BRCA2 DNA repair associated Homo sapiens
4 Here, we present a patient harboring a pathogenic BRCA germline variant whose PDAC grew rapidly during platinum-based therapy and lacked BRCA LOH and therefore was not likely BRCA-related. Platinum BRCA2 DNA repair associated Homo sapiens
5 Given the molecular fingerprint of BRCA-related PDAC in patients with pathogenic BRCA germline variants and the mechanism of action of platinum-based therapies and PARP inhibitors, this case underscores the importance of future studies aimed at determining whether the lack of BRCA LOH in PDACs in pathogenic BRCA germline variant carriers is a biomarker of less responsiveness to platinum-based chemotherapy and PARP inhibitors. Platinum BRCA2 DNA repair associated Homo sapiens